Novo Nordisk's largest market for the weight loss drug Wegovy is the USA. On Thursday, disappointing results from an American competitor have given a boost to Novo's stock. (Archive photo). Photo: Sergei Gapon/Ritzau Scanpix
Disappointing rival results boost Novo stock
Novo Nordisk’s stock saw a significant rise on Thursday afternoon, increasing by over 12% around 1:30 PM. The surge occurred after Eli Lilly in the US released results from a trial of a new weight-loss pill, which disappointed investors and led to an 11% drop in Eli Lilly’s stock. The trial...
Get full access to Danish News in English
Gain exclusive access to daily news updates in English pertaining to Denmark with a Ritzau News subscription.
Already a subscriber?